Ligand-induced ErbB receptor dimerization.
暂无分享,去创建一个
[1] P. Sternberg,et al. A point mutation in the extracellular domain activates LET-23, the Caenorhabditis elegans epidermal growth factor receptor homolog , 1996, Molecular and cellular biology.
[2] Joseph Schlessinger,et al. Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.
[3] G. M. Walton,et al. Structural analysis of the transmembrane domain of the epidermal growth factor receptor. , 1991, The Journal of biological chemistry.
[4] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[5] Michael Kofler,et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.
[6] Nathan E Hall,et al. CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor* , 2004, Journal of Biological Chemistry.
[7] A. M. Stanley,et al. Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .
[8] Peter Klein,et al. On the nature of low- and high-affinity EGF receptors on living cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[9] M. Sliwkowski,et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.
[10] T. Wohland,et al. Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy. , 2007, Biophysical journal.
[11] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[12] David Eisenberg,et al. Heregulin reverses the oligomerization of HER3. , 2000 .
[13] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[14] P. D. Meyts,et al. The insulin receptor: a prototype for dimeric, allosteric membrane receptors? , 2008 .
[15] A. Ullrich,et al. A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor , 1986, Nature.
[16] G. Carpenter,et al. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation , 2007, Proceedings of the National Academy of Sciences.
[17] Martyn D Winn,et al. Single-molecule imaging and fluorescence lifetime imaging microscopy show different structures for high- and low-affinity epidermal growth factor receptors in A431 cells. , 2008, Biophysical journal.
[18] R. Bose,et al. The ErbB kinase domain: structural perspectives into kinase activation and inhibition. , 2009, Experimental cell research.
[19] Antony W Burgess,et al. Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.
[20] A. Ullrich,et al. Ligand-induced stimulation of epidermal growth factor receptor mutants with altered transmembrane regions. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[21] Jae-Hoon Kim,et al. Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.
[22] Linda J Pike,et al. Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system , 2008, Proceedings of the National Academy of Sciences.
[23] A. Ullrich,et al. Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells. , 1986, The Journal of biological chemistry.
[24] M. Sliwkowski,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.
[25] A. Berezov,et al. Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics* , 2002, The Journal of Biological Chemistry.
[26] Peter Klein,et al. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] H. Blau,et al. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions , 2006, Proceedings of the National Academy of Sciences.
[28] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[29] D. Murray,et al. An Electrostatic Engine Model for Autoinhibition and Activation of the Epidermal Growth Factor Receptor (EGFR/ErbB) Family , 2005, The Journal of general physiology.
[30] D. Engelman,et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer , 1997, The EMBO journal.
[31] E. Mekada,et al. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. , 2002, Molecular biology of the cell.
[32] J. Beechem,et al. Preparation and characterization of Alexa Fluor 594-labeled epidermal growth factor for fluorescence resonance energy transfer studies: application to the epidermal growth factor receptor. , 2004, Analytical biochemistry.
[33] P. D. Meyts,et al. The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling , 1994, Diabetologia.
[34] Ron Bose,et al. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. , 2008, Structure.
[35] M. Lemmon,et al. Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors , 2000, The EMBO journal.
[36] J. Schlessinger,et al. Allosteric regulation of the epidermal growth factor receptor kinase , 1986, The Journal of cell biology.
[37] A. Citri,et al. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.
[38] K Lund,et al. Implications of epidermal growth factor (EGF) induced egf receptor aggregation. , 1992, Biophysical journal.
[39] N. Hynes,et al. ErbB receptors: directing key signaling networks throughout life. , 2004, Annual review of pharmacology and toxicology.
[40] G. Todaro,et al. Biologically active phorbol esters specifically alter affinity of epidermal growth factor membrane receptors , 1979, Nature.
[41] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[42] E C Nice,et al. Stoichiometry, Kinetic and Binding Analysis of the Interaction between Epidermal Growth Factor (EGF) and the Extracellular Domain of the EGF Receptor , 2000, Growth factors.
[43] M. Sliwkowski,et al. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.
[44] L. Matrisian,et al. Epidermal growth factor. Ability of tumor promoter to alter its degradation, receptor affinity and receptor number. , 1980, The Journal of biological chemistry.
[45] I. Lax,et al. Ligand-binding enhances the affinity of dimerization of the extracellular domain of the epidermal growth factor receptor. , 1997, Journal of biochemistry.
[46] J. Schlessinger,et al. Signal transduction by allosteric receptor oligomerization. , 1988, Trends in biochemical sciences.
[47] T. Hazlett,et al. Structure and dynamics of the epidermal growth factor receptor C‐terminal phosphorylation domain , 2006, Protein science : a publication of the Protein Society.
[48] G. Carpenter,et al. ErbB-4: mechanism of action and biology. , 2003, Experimental cell research.
[49] Y. Teramura,et al. Single‐molecule analysis of epidermal growth factor binding on the surface of living cells , 2006, EMBO Journal.
[50] Joseph Schlessinger,et al. SH2 and PTB Domains in Tyrosine Kinase Signaling , 2003, Science's STKE.
[51] J. Sturgis,et al. A dimerization hierarchy in the transmembrane domains of the HER receptor family. , 2007, Biochemistry.
[52] R. Kumar,et al. Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. , 1991, The Journal of biological chemistry.
[53] J. Schlessinger. Autoinhibition Control , 2003, Science.
[54] M. Lemmon,et al. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface , 2004, FEBS letters.
[55] A. Chantry. The kinase domain and membrane localization determine intracellular interactions between epidermal growth factor receptors. , 1995, The Journal of biological chemistry.
[56] R. Jorissen,et al. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. , 2001, Biochemistry.
[57] I. Maruyama,et al. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells , 2008, Journal of Cell Science.
[58] Hyun-soo Cho,et al. Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.
[59] J. Schlessinger,et al. Epidermal Growth Factor Receptor Dimerization and Activation Require Ligand-Induced Conformational Changes in the Dimer Interface , 2005, Molecular and Cellular Biology.
[60] Samuel Bouyain,et al. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[61] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[62] Edouard C. Nice,et al. Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis* , 2005, Journal of Biological Chemistry.
[63] N. Mckern,et al. High affinity insulin binding by soluble insulin receptor extracellular domain fused to a leucine zipper , 2000, FEBS letters.
[64] M. Lemmon,et al. Ligand-induced structural transitions in ErbB receptor extracellular domains. , 2007, Structure.
[65] J. Carlsson,et al. Binding of epidermal growth factor (EGF) to a cultured human glioma cell line. , 1991, Journal of receptor research.
[66] P. Jeffrey,et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.
[67] P. Sternberg,et al. Extracellular domain determinants of LET-23 (EGF) receptor tyrosine kinase activity in Caenorhabditis elegans , 2003, Oncogene.
[68] M. Lemmon,et al. The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes* , 2002, The Journal of Biological Chemistry.
[69] E. Elson,et al. Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis. , 2007, Biophysical journal.
[70] Y. Yarden,et al. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. , 1987, Biochemistry.
[71] H. Kitano,et al. A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.
[72] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[73] Edouard C. Nice,et al. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.
[74] M. Lawrence,et al. The insulin and EGF receptor structures: new insights into ligand-induced receptor activation. , 2007, Trends in biochemical sciences.
[75] Colin W. Ward,et al. The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules , 2001, BMC Bioinformatics.
[76] M. Martin-Fernandez,et al. Preformed oligomeric epidermal growth factor receptors undergo an ectodomain structure change during signaling. , 2002, Biophysical journal.
[77] Y. Yarden,et al. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. , 1987, Biochemistry.
[78] Jonathan A. Cooper,et al. Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane , 1984, Nature.
[79] I. Maruyama,et al. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. , 2001, Journal of molecular biology.
[80] M. Sliwkowski,et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.
[81] T. Walz,et al. Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. , 2008, Biochemistry.
[82] M. Sliwkowski,et al. Identification of a Region within the ErbB2/HER2 Intracellular Domain That Is Necessary for Ligand-independent Association* , 2002, The Journal of Biological Chemistry.
[83] Toshio Yanagida,et al. Single-molecule imaging of EGFR signalling on the surface of living cells , 2000, Nature Cell Biology.
[84] D. Davies,et al. A unified model of c-erbB receptor homo- and heterodimerisation. , 1998, Biochimica et biophysica acta.
[85] S. Gabriel,et al. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.
[86] D. Gross,et al. Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity. , 2000, The Biochemical journal.
[87] D. Vlachos,et al. Heterogeneities in EGF receptor density at the cell surface can lead to concave up scatchard plot of EGF binding , 2005, FEBS letters.
[88] K. Ferguson,et al. Structure-based view of epidermal growth factor receptor regulation. , 2008, Annual review of biophysics.
[89] Joseph Schlessinger,et al. Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor , 2002, Cell.
[90] N. Mckern,et al. The three dimensional structure of the type I insulin-like growth factor receptor , 2001, Molecular pathology : MP.
[91] D. Steiner,et al. Fusion of Insulin Receptor Ectodomains to Immunoglobulin Constant Domains Reproduces High-affinity Insulin Binding in Vitro* , 1996, The Journal of Biological Chemistry.
[92] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[93] A. Ullrich,et al. High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses , 1990, The Journal of cell biology.
[94] T. Hunter,et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors , 1989, The Journal of cell biology.
[95] Peter Klein,et al. A structure-based model for ligand binding and dimerization of EGF receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[96] Hyun-soo Cho,et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.
[97] T M Jovin,et al. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation , 1995, The Journal of cell biology.
[98] T. Arakawa,et al. Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3 (*) , 1995, The Journal of Biological Chemistry.